Pregabalin Zentiva

Country: European Union

Language: Romanian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalin

Available from:

Zentiva, k.s.

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptice,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Neuropathic pain , Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , Epilepsy , Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , Generalised anxiety disorder , Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.

Product summary:

Revision: 15

Authorization status:

Autorizat

Authorization date:

2015-07-17

Patient Information leaflet

                                50
B. PROSPECTUL
51
PROSPECT: INFORMAŢII PENTRU
UTILIZATOR
PREGABALIN ZENTIVA 25 MG CAPSULE
PREGABALIN ZENTIVA 50 MG CAPSULE
PREGABALIN ZENTIVA 75 MG CAPSULE
PREGABALIN ZENTIVA 100 MG CAPSULE
PREGABALIN ZENTIVA 150 MG CAPSULE
PREGABALIN ZENTIVA 200 MG CAPSULE
PREGABALIN ZENTIVA 225 MG CAPSULE
PREGABALIN ZENTIVA 300 MG CAPSULE
pregabalin
ă
CITIŢI CU ATENŢIE ŞI
ÎN ÎNTREGIME ACEST PROSPECT ÎNAINTE DE A ÎNCEPE SĂ LUAŢI ACEST
MEDICAMENT
DEOARECE CONŢINE INFORMAŢII IMPORTANTE PENTRU DUMNEAVOASTRĂ.
-
Păstraţi acest prospect. S
-
ar putea să fie necesar să
-
l recitiţi.
-
Dacă aveţi orice întrebări suplimentare, adresaţi
-
vă medicului dumneavoastră sau farmacistului
.
-
Acest medicament a fost prescris numai
pentru dumneavoastră. Nu trebuie să
-
l daţi altor
persoane. Le poate face rău, chiar dacă au aceleaşi semne de boală
ca
dumneavoastră.
-
Dacă manifestaţi orice reacţii
adverse, a
dresaţi
-
vă medicului dumneavoastră sau farmacistului
.
Acestea includ orice posibile reacţii adverse nemenţionate în acest
prospect. Vezi pct. 4.
CE GĂSIŢI ÎN ACEST PROSPECT:
1.
Ce este Pregabalin
Zentiva şi pentru ce se utilizează
2.
Ce trebuie să ştiţi înainte să luaţi
Pregabalin Zentiva
3.
Cum să luaţi
Pregabalin Zentiva
4.
Reacţii adverse posibile
5.
Cum se păstrează
Pregabalin Zentiva
6.
Conţinutul ambalajului şi alte informaţii
1.
CE ESTE PREGABALIN
ZENTIVA ŞI PENTRU CE SE UTILIZEAZĂ
Pregabalin Zentiva aparţine unui grup de medicamente utilizate pentru
a trata epilepsia
, durerea
neuropat
ă
şi tulburarea anxioasă generalizată (TAG) la adulţi.
DUREREA NEUROPAT
Ă PERIFERIC
Ă
Ş
I CENTRAL
Ă
Pregabalin Zentiva este utilizat pentru a trata durerea cronic
ă determinat
ă
de lezarea nervilor. O mare
varietate de boli pot determina durere neuropat
ă
, cum sunt diabetul zaharat sau zona zoster. Senza
ţ
iile
de durere pot fi descrise ca
ş
i caldur
ă
, arsur
ă
, pulsa
ţ
ie, junghi, în
ţ
ep
ă
tur
ă
, crampe, furnic
ă
turi, amor
ţ
eli,
furnic
ă
turi dup
ă
am
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANEXA I
REZUMATUL CARACTERISTICILOR PRODUSULUI
2
1.
DENUMIREA COMERCIALĂ A MEDICAMENTULUI
Pregabalin Zentiva 25 mg capsule
Pregabalin Zentiva 50 mg capsule
Pregabalin Zentiva 75 mg capsule
Pregabalin Zentiva 100 mg capsule
Pregabalin Zentiva 150 mg capsule
Pregabalin Zentiva 200 mg capsule
Pregabalin Zentiva 225 mg capsule
Pregabalin Zentiva 300 mg capsule
2.
COMPOZIŢIA CALITATIVĂ ŞI CANTITATIVĂ
Pregabalin Zentiva 25 mg capsule
Fiecare
capsulă
conţine
pregabalin
ă
25 mg.
Excipient cu efect cunoscut
Fiecare
capsulă
conţine
şi lactoză
monohidrat 47,57 mg.
Pregabalin Zentiva 50 mg capsule
Fiecare capsulă conţine pregabalină 50 mg.
Excipient cu efect cunoscut
F
iecare capsulă conţine şi lactoză
monohidrat 5 mg.
Pregabalin Zentiva 75 mg capsule
Fiecare capsulă conţine pregabalină 75 mg.
Excipient cu efect cunoscut
F
iecare capsulă conţine şi lactoză
monohidrat 7,5 mg.
Pregabalin Zentiva 100 mg capsule
Fiecare capsulă conţine pregabalină 100 mg.
Excipient cu efect cunoscut
F
iecare capsulă conţine şi lactoză
monohidrat 10 mg.
Pregabalin Zentiva 150 mg capsule
Fiecare capsulă conţine pregabalină 150 mg.
Excipient cu efect cunoscut
F
iecare capsulă conţine şi
lactoză
monohidrat 15 mg.
Pregabalin Zentiva 200 mg capsule
Fiecare capsulă conţine pregabalină 200 mg.
Excipient cu efect cunoscut
F
iecare capsulă conţine şi lactoză
monohidrat 20 mg.
Pregabalin Zentiva 225 mg capsule
Fiecare capsulă conţine pregabalină 225 mg.
Excipient cu efect cunoscut
F
iecare capsulă conţine şi lactoză
monohidrat 22,5 mg.
3
Pregabalin Zentiva 300 mg capsule
Fiecare capsulă conţine pregabalină 300 mg.
Excipient cu efect cunoscut
F
iecare capsulă conţine şi lactoză
monohidrat 30 mg.
Pentru lista tuturor excipienţilor, vezi pct. 6.1.
3.
FORMA FARMACEUTICĂ
Capsule
Pregabalin Zentiva 25 mg capsule
C
apac gri deschis şi corp gri deschis
; capsul
ă
gelatinoas
ă
inscripţionată
cu „25”, cu lungimea de
aproximativ 15,9 mm, car
e conţin
e
o pulbere aproape albă.
Pregabalin Zenti
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-07-2015
Patient Information leaflet Patient Information leaflet Spanish 19-03-2024
Public Assessment Report Public Assessment Report Spanish 27-07-2015
Patient Information leaflet Patient Information leaflet Czech 19-03-2024
Public Assessment Report Public Assessment Report Czech 27-07-2015
Patient Information leaflet Patient Information leaflet Danish 19-03-2024
Public Assessment Report Public Assessment Report Danish 27-07-2015
Patient Information leaflet Patient Information leaflet German 19-03-2024
Public Assessment Report Public Assessment Report German 27-07-2015
Patient Information leaflet Patient Information leaflet Estonian 19-03-2024
Public Assessment Report Public Assessment Report Estonian 27-07-2015
Patient Information leaflet Patient Information leaflet Greek 19-03-2024
Public Assessment Report Public Assessment Report Greek 27-07-2015
Patient Information leaflet Patient Information leaflet English 19-03-2024
Public Assessment Report Public Assessment Report English 27-07-2015
Patient Information leaflet Patient Information leaflet French 19-03-2024
Public Assessment Report Public Assessment Report French 27-07-2015
Patient Information leaflet Patient Information leaflet Italian 19-03-2024
Public Assessment Report Public Assessment Report Italian 27-07-2015
Patient Information leaflet Patient Information leaflet Latvian 19-03-2024
Public Assessment Report Public Assessment Report Latvian 27-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 19-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-07-2015
Patient Information leaflet Patient Information leaflet Maltese 19-03-2024
Public Assessment Report Public Assessment Report Maltese 27-07-2015
Patient Information leaflet Patient Information leaflet Dutch 19-03-2024
Public Assessment Report Public Assessment Report Dutch 27-07-2015
Patient Information leaflet Patient Information leaflet Polish 19-03-2024
Public Assessment Report Public Assessment Report Polish 27-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 19-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 19-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-07-2015
Patient Information leaflet Patient Information leaflet Slovak 19-03-2024
Public Assessment Report Public Assessment Report Slovak 27-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 19-03-2024
Public Assessment Report Public Assessment Report Slovenian 27-07-2015
Patient Information leaflet Patient Information leaflet Finnish 19-03-2024
Public Assessment Report Public Assessment Report Finnish 27-07-2015
Patient Information leaflet Patient Information leaflet Swedish 19-03-2024
Public Assessment Report Public Assessment Report Swedish 27-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 19-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 19-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 19-03-2024
Patient Information leaflet Patient Information leaflet Croatian 19-03-2024
Public Assessment Report Public Assessment Report Croatian 27-07-2015

Search alerts related to this product